Germany Infectious Disease Therapeutics Market Analysis

Germany Infectious Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the German infectious disease therapeutics market will reach a value of $5.37 Bn from $4.39 Bn in 2022, growing at a CAGR of 2.6% during 2022-2030.

Germany is a high-income, developed country located in the heart of Western Europe. Immunotherapies, which use the body's immune system to combat infectious diseases, are increasingly gaining popularity in Germany. These medicines, which provide a tailored and successful approach to infectious illness therapy, are predicted to gain popularity in the future years. According to WHO figures, TB treatment coverage in Germany is roughly 61 %. In 2020, the leading notifiable infectious disease was coronavirus disease (COVID-19).

The COVID-19 pandemic not only imposed a massive strain on Germany's public health system, but it also influenced the occurrence and detection of other notifiable infectious diseases. The Infection Protection Act is continuously updated to reflect changes in the epidemiological situation in Germany and around the world. Germany's government spends 12.8 % of its GDP on healthcare.

Market Dynamics

Market Growth Drivers Analysis

While infectious illness rates in Germany have been relatively low in recent years, several infectious diseases, such as tuberculosis, hepatitis C, and sexually transmitted infections, have recently increased (STIs). This has increased the demand for effective treatments to treat these disorders. The German government is investing in infectious illness research, including the development of novel medicines and vaccinations. Germany has a low structural unemployment rate and a well-developed apprenticeship system These aspects could boost Germany's infectious disease therapeutics market.

Market Restraints

Germany has a strict drug clearance process, and the German regulatory body, the Federal Institute for Drugs and Medical Devices (BfArM), is well-known for its demanding safety and efficacy standards. This can make it difficult for pharmaceutical companies to get their infectious illness medicines approved and marketed in the country. While Germany has a robust healthcare system, it remains vulnerable to developing infectious diseases, which can pose new obstacles to pharmaceutical development and dissemination. Despite immigration, the working population is expected to decline beginning in 2020. These factors may deter new entrants into the German infectious disease therapeutics market.

Competitive Landscape

Key Players

• CureVac: CureVac is a biopharmaceutical company that specializes in the development of vaccines and immunotherapies. The company is based in Tübingen, Germany. CureVac is currently working on a COVID-19 vaccine
• BioNTech: BioNTech is a biotechnology company based in Mainz, Germany. The company focuses on the development of immunotherapies for cancer and infectious diseases. BioNTech is one of the companies that developed a COVID-19 vaccine in collaboration with Pfizer
• Evotec: Evotec is a drug discovery and development company based in Hamburg, Germany. The company focuses on the development of drugs for infectious diseases, including bacterial and viral infections
• AiCuris: AiCuris is a biotech company that develops drugs for viral and bacterial infections, including HIV, hepatitis B, and cytomegalovirus. The company is based in Wuppertal, Germany
• InfectoPharm: InfectoPharm is a German pharmaceutical company that specializes in the development of drugs for infectious diseases, including bacterial and viral infections

Recent Notable Updates

July 2021: The Global Antibiotic Research and Development Partnership (GARDP) and InfectoPharm are collaborating to discover improved treatment options for neonatal sepsis, a leading cause of mortality and impairment in babies up to 28 days old, using combinations of existing antibiotics. Because children of this age lack a functioning immune system, they are more susceptible to infection and less able to overcome it.

Healthcare Policies and Reimbursement Scenarios

The regulation of infectious disease therapies in Germany is the responsibility of the Federal Institute for Medications and Medical Devices (BfArM), which is in charge of reviewing and approving novel drugs and medical devices. The approval procedure for infectious disease treatments in Germany encompasses numerous steps, including preclinical testing, clinical trials, and marketing authorization. Before initiating clinical trials, the producer must submit an application to the BfArM, which will assess the proposed drug's safety and efficacy. If the application is granted, the firm will be able to begin clinical testing. Other regulatory agencies in Germany, in addition to the BfArM, may be involved in the regulation of infectious disease treatments. For example, the Paul Ehrlich Institute (PEI) is responsible for evaluating the safety and efficacy of vaccines and blood products.

The reimbursement of infectious illness treatments in Germany is essentially governed by the statutory health insurance system. This system covers more than 85 % of the German population, and drug reimbursement is overseen by the Federal Joint Committee (G-BA) and the Institute for Quality and Efficiency in Health Care (IQWiG).